ADASUVE Drug Patent Profile

When do Adasuve patents expire, and when can generic versions of Adasuve launch?

Adasuve is a drug marketed by Nova Pneuma and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-one patent family members in six countries.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. Additional details are available on the loxapine profile page.

DrugPatentWatch^® Generic Entry Outlook for Adasuve

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 23, 2026. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ADASUVE

International Patents:	21
US Patents:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADASUVE

US Patents and Regulatory Information for ADASUVE

ADASUVE is protected by one US patents.

This potential generic entry date is based on patent 8,387,612.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Nova Pneuma	ADASUVE	loxapine	POWDER;INHALATION	022549-001	Dec 21, 2012		RX	Yes	Yes	8,387,612		Y

International Patents for ADASUVE

See the table below for patents covering ADASUVE around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	60230609
Australia	2007231750	Method of forming an aerosol for inhalation delivery
Japan	2004531556
Hong Kong	1081888	METHOD AND APPARATUS FOR VAPORIZING A COMPOUND
Austria	401064
Canada	2446917	ADMINISTRATION D'ANTIPSYCHOTIQUES PAR INHALATION (DELIVERY OF ANTIPSYCHOTICS THROUGH AN INHALATION ROUTE)

Supplementary Protection Certificates for ADASUVE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1389098	CR 2013 00046	Denmark		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098	C01389098/01	Switzerland		PRODUCT NAME: LOXAPINUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65461 13.12.2016
1389098	CA 2013 00046	Denmark		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
1389098	300609	Netherlands		PRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
1389098	1390040-2	Sweden		PRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
1389098	SPC/GB13/055	United Kingdom		PRODUCT NAME: LOXAPINE; REGISTERED: UK EU/1/13/823/001 20130220; UK EU/1/13/823/002 20130220

ADASUVE (Loxapine) Investment Scenario and Fundamentals Analysis

Last updated: April 25, 2026

What is ADASUVE and what is the commercial footprint?

ADASUVE is an inhaled formulation of loxapine indicated for acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. The product is delivered via a patient inhalation system and is positioned for rapid onset in acute care settings.

Core investment framing

• Revenue engine: acute agitation episodes treated in settings that adopt inhaled loxapine.
• Competitive pressure: alternative acute agitation pathways (other antipsychotics and short-acting formulations) plus substitution risk when payers limit access.
• Execution risk: channel contracting, formulary inclusion, and adherence to REMS-adjacent operational requirements in practice settings.

Who markets ADASUVE and what is the ownership structure?

ADASUVE is marketed in the US by Teva Pharmaceuticals (brand/label ownership and commercialization rights in the US context). The commercial strategy depends on Teva’s hospital and payer contracting, plus guidance-driven prescribing for acute agitation.

What does the patent and exclusivity landscape imply for risk timing?

For ADASUVE, the investment case is dominated by two time-linked risk drivers:

1. Brand exclusivity end (licenseable manufacturing and generic entry dynamics).
2. Formulation and method-of-use patent fences that can extend or blunt generic substitution.

Without an explicitly provided patent table, the only defensible statement for an investment model is that ADASUVE’s fundamentals should be modeled with:

• near-term demand stability assumptions until exclusivity cliffs
• material downside sensitivity to generic erosion once approved and reimbursed

How does indication scope shape demand durability?

ADASUVE is focused on acute agitation rather than chronic maintenance. This matters for forecasting because:

• Episode-based demand is cyclical with hospital utilization patterns.
• Adoption is protocol-driven: clinicians use inhaled loxapine when it fits agitation management algorithms.

That narrower use case supports a more stable base when hospitals build protocols, but it also increases substitution risk if comparators are preferred for formulary or workflow reasons.

What are the key clinical and practical drivers affecting utilization?

In acute agitation, utilization is driven by:

• speed-to-effect expectations in emergency and inpatient agitation settings
• patient cooperation and inhalation feasibility, which can limit use in more disturbed or uncooperative patients
• safety and tolerability profile, influencing whether institutions stock and use it consistently

These factors determine whether ADASUVE remains a default within agitation protocols or becomes a secondary option after formulary updates.

What competitive alternatives pressure ADASUVE’s pricing and volume?

ADASUVE competes indirectly with multiple acute agitation strategies:

• intramuscular or IV antipsychotics in emergency and inpatient settings
• other rapid-acting antipsychotic options that may have broader institutional comfort
• non-pharmacologic de-escalation workflows that can reduce medication frequency in some settings

From a fundamentals lens, competition pressure typically shows up as:

• lower net prices from formulary tiers or rebate tightening
• lower administered volume if institutions standardize a different acute regimen

How does reimbursement influence net sales?

ADASUVE’s investment sensitivity is high to:

• payer acceptance (coverage policies for acute agitation)
• site-of-care contracting (hospital pharmacy formularies)
• pharmacy procurement (tendering and inventory decisions)

Reimbursement tightening tends to reduce net revenue even when total episodes treated remain stable.

What should investors model in an ADASUVE unit economics view?

Because ADASUVE is episode-driven, the model should separate:

• Episode frequency treated (units)
• Net price (after rebates and payer mix)
• Channel mix (inpatient vs emergency vs other institutional channels)
• Adoption rate (share of hospitals and clinicians using inhaled loxapine)

Scenario framework (investment-grade structure)

Driver	Bull case	Base case	Bear case
Hospital protocol adoption	Wide protocol inclusion sustains share	Gradual stabilization with selective uptake	Loss of protocols to comparator pathways
Net price	Limited payer pushback	Moderate rebate pressure	Aggressive formulary tier changes reduce net
Competitive/generic erosion	Delayed market entry or limited uptake	Controlled erosion with partial retention	Rapid substitution and steep unit decline
Safety/practical access	Stocking expands as workflows fit	Stable access with minor friction	Stockouts or reduced use due to workflow constraints
Demand elasticity	Episodes treated remain steady	Episode volatility offsets price gains	Lower treated share per episode

What are the principal investment risks and upside levers?

What are the upside levers?

• Protocol retention in high-volume inpatient and emergency systems
• Payer coverage durability (maintained access without restrictive prior authorization changes)
• Sustained clinician familiarity driving continued use within acute agitation algorithms

What are the key downside risks?

• Generic entry and substitution after exclusivity barriers fall
• Net price erosion from payer contracting and rebate tightening
• Workflow friction reducing inhaled utilization in real-world agitation settings

What fundamentals checklist matters for diligence?

A high-quality diligence pack for ADASUVE should focus on:

• Hospital formulary penetration by region and system type
• Net price and rebate trend (quarter-by-quarter)
• Unit throughput and administered volumes, not only prescriptions
• Share shifts versus comparator acute agitation pathways
• Regulatory and labeling stability (any changes affecting eligibility or administration)

How should the investment scenario be sized for valuation work?

Given the episode-based nature and patent/exclusivity sensitivity, valuation should be built from:

• a unit-volume forecast tied to protocol adoption and episode treatment share
• a net-price forecast tied to payer mix and rebate trend
• a generic substitution overlay that ramps based on:
  • approval timing
  • formulary uptake
  • tender and procurement adjustments

A practical approach is to run discounted cash flow with:

• two exclusivity paths (delayed vs earlier erosion)
• three adoption paths (steady vs gradual decline vs acceleration of substitution)

Key Takeaways

• ADASUVE is an acute, episode-driven branded product in agitation associated with schizophrenia or bipolar I disorder; volume depends on protocol adoption in acute care settings.
• Investment sensitivity is highest to exclusivity and reimbursement: generic substitution and payer contracting can move both units and net price.
• The fundamentals model should separate episodes treated, administered unit throughput, net price, and channel mix, then layer protocol adoption and substitution ramp.
• Upside comes from stable payer access and durable hospital protocols; downside comes from rapid generic erosion and formulary displacement.

FAQs

1. Is ADASUVE used for chronic schizophrenia or bipolar maintenance?
   No. ADASUVE is indicated for acute treatment of agitation in adults associated with schizophrenia or bipolar I disorder.

2. What drives ADASUVE demand in practice?
   Demand tracks acute agitation episode management and the extent to which hospitals and clinicians embed inhaled loxapine into agitation protocols.

3. Where does substitution pressure typically show up first?
   Typically through net price compression and then unit share loss as institutions shift to alternative acute agitation pathways or generic equivalents after entry.

4. What matters most for net sales forecasting?
   Net price after rebates, administered unit volumes, and channel mix (inpatient vs emergency procurement and formularies).

5. How should patent risk be handled in valuation?
   Model valuation with an explicit exclusivity cliff and substitution ramp, since branded acute products can lose both volume and price quickly when generic access expands.

References

[1] ADASUVE (loxapine) Prescribing Information. Teva Pharmaceuticals. (US label).